Features of the appearance of clinical cardiomyopathies against the background of truncating variants in the ttn gene: a review of the literature and an analysis of the appearance.

Background. To date, the influence of genetic variants in the titin gene on the development of all types of cardiomyopathies has been proven, and this primarily applies to TTNtv, however, the high frequency of these variants in the control population (1–3 %) significantly complicates the determination of the pathogenicity of the detected variants. In addition, due to a significant population frequency (1–3 %) in patients with CMP, variants in the titin gene are often combined with causal variants in other genes, and thus can act as modifiers of the clinical course of the disease and myocardial remodeling.

Objective. To study the effect of shortening variants in the titin gene on the clinical course of cardiomyopathies in the presence of causative variants in other genes or etiological factors of the disease.

Design and methods. This article will consider three clinical cases of patients diagnosed with CMP who were treated at the Almazov National Medical Research Center. To conduct a genetic examination, next generation sequencing was used with a target cardiopanel to check 108 genes associated with the development of cardiomyopathies, as well as Sanger sequencing to exclude false positive results.

Results. During a genetic examination of the studied patients, identified genetic variants in the titin gene led to the syn- thesis of a truncated protein: in all cases, the reason for this was frameshift deletions located in exons with a PSI (Percent Spliced-In) level of 100%. According to the American College of Medical Genetics and Genomics pathogenicity classification, two genetic variants are classified as pathogenic and one is classified as probably pathogenic.

Conclusion. In these patients, we found shortening variants (frameshift deletions) in the titin gene, which acted as modifiers of myocardial remodeling.

1. Linke WA. Sense and stretchability: The role of titin and titin-associated proteins in myocardial stresssensing and mechanical dysfunction †.

2. Linke WA, Hamdani N. Gigantic business: Titin properties and function through thick and thin. Circ Res. 2014;114(6):1052–68.

3. Opitz CA, Leake MC, Makarenko I, et al. Developmentally Regulated Switching of Titin Size Alters Myofibrillar Stiffness in the Perinatal Heart. Circ Res. 2004 Apr 16;94(7):967–75.

4. Bang ML, Centner T, Fornoff F, et al. The complete gene sequence of titin, expression of an unusual ≈700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ Res. 2001 Nov 23;89(11):1065–72.

5. Vikhlyantsev IM, Podlubnaya ZA. Isoform composition of titin in muscles during pathological processes. Biochemistry (Mosc). 2008;53(6):1058–1072. In Russian

6. Guo W, Schafer S, Greaser ML, et al. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med. 2012 May;18(5):766–73.

7. Grützner A, Garcia-Manyes S, Kötter S, et al. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J. 2009;97(3):825–34.

8. Tabish AM, Azzimato V, Alexiadis A, et al. Genetic epidemiology of titin-truncating variants in the etiology of dilated cardiomyopathy. Biophys Rev. 2017 Jun 1;9(3):207–23.

9. Xu YC, Guo YL. Less Is More, Natural Lossof-Function Mutation Is a Strategy for Adaptation. Plant Commun. 2020 Nov 9;1(6):100103.

10. Vakhrushev YuA, Vershinina TI, Fedotov PA, et al. Left ventricular noncompaction associated with titintruncating variants in the TTN gene. Russian Journal of Cardiology. 2020;25(10):4027. In Russian

11. Carmignac V, Salih MAM, Quijano-Roy S, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol. 2007;61(4):340–351.

12. Ceyhan-Birsoy O, Agrawal PB, Hidalgo C, et al. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology. 2013 Oct 1;81(14):1205–14.

13. Haggerty CM, Damrauer SM, Levin MG, et al. Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. Circulation. 2019 Jul 2;140(1):42–54.

14. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–778.

15. Chauveau C, Rowell J, Ferreiro A. A rising titan: TTN review and mutation update. Hum Mutat. 2014;35(9):1046–59.

16. Hinson JT, Chopra A, Nafissi N, Polacheck WJ, et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015 Aug 28;349(6251):982–6.

17. Roberts AM, Ware JS, Herman DS, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015 Jan 14;7(270).

18. Gramlich M, Michely B, Krohne C, et al. Stressinduced dilated cardiomyopathy in a knock-in mouse model mimicking human titin-based disease. J Mol Cell Cardiol. 2009 Sep;47(3):352–8.

19. Lunde IG, Wakimoto H, Burke MA, et al. Titin A–band truncation in mice causes stress–induced dilated cardiomyopathy. Eur J Heart Fail. 2015;7(1):31.

20. Van Spaendonck-Zwarts KY, Posafalvi A, Van Den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014 Aug 21;35(32):2165–73.

21. Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J Am Coll Cardiol. 2018;71(20):2293–2302.

22. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation. 2019 Jul 2;140(1):31–41.

23. Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 Feb 16;366(7):619–28.

24. Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by highthroughput sequencing. J Med Genet. 2013;50(4):228–39.

25. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015 May 7;36(18):1123–35.

26. Gerull B. The Rapidly Evolving Role of Titin in Cardiac Physiology and Cardiomyopathy. Can J Cardiol. 2015;31(11):1351–9.

27. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005 Jul 5;46(1):101–5.

28. Jorholt J, Formicheva Y, Vershinina T, et al. Two new cases of hypertrophic cardiomyopathy and skeletal muscle features associated with alpk3 homozygous and compound heterozygous variants. Genes (Basel). 2020 Oct 1;11(10):1–9.

29. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 1;121(7):749–70.

30. Chintanaphol M, Orgil BO, Alberson NR, et al. Restrictive cardiomyopathy: from genetics and clinical overview to animal modeling. Rev Cardiovasc Med. 2022 Mar 1;23(3).

31. Zhang C, Zhang H, Wu G, et al. Titin-Truncating Variants Increase the Risk of Cardiovascular Death in Patients With Hypertrophic Cardiomyopathy. Can J Cardiol. 2017 Oct 1;33(10):1292–7.